Suppliers / Zhejiang Hengkang Pharmaceutical

Zhejiang Hengkang Pharmaceutical

China 10 employees Updated 9 July 2026

Zhejiang Hengkang Pharmaceutical is an API manufacturer based in China. It holds 3 active US drug master files and 9 valid CEPs across a filed portfolio of 8 molecules. Its GMP standing is certified by EMA and US FDA. Its most recent recorded inspection, by US FDA, closed on 7 March 2025 as NAI.

3
active US DMFs
9
valid CEPs
2
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
1 of 1 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 7 March 2025 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Sanmen, China Not on file
China, China 3022190702

What they file, and where

Molecule Regulators Docs
Mesalazine EDQM, US FDA 3
Deferasirox EDQM, US FDA 2
Tenoxicam EDQM 2
Acemetacin EDQM 1
Amiodarone Hydrochloride EDQM 1
Benserazide EDQM 1
Benserazide Hydrochloride EDQM 1
Eltrombopag US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
EMA None 2
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Zhejiang Hengkang Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 7 March 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates